🇺🇸 FDA
Patent

US 12415843

Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer

granted A61KA61K2039/505A61K2239/48

Quick answer

US patent 12415843 (Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer) held by The Regents of the University of California expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/505, A61K2239/48, A61K38/21, A61K38/212